אדסל פוליו

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

DIPHTHERIA TOXOID; FILAMENTOUS HAEMAGGLUTININ (FHA); FIMBRAE TUPES 2 + 3 (FIM); INACTIVATED POLIO VIRUS (IPV) TYPE 1; INACTIVATED POLIO VIRUS (IPV) TYPE 2; INACTIVATED POLIO VIRUS (IPV) TYPE 3; PERTACTIN (PRN); PERTUSSIS TOXOID VACCINE; TETANUS TOXOID

Disponible depuis:

SANOFI ISRAEL LTD

Code ATC:

J07CA02

forme pharmaceutique:

תרחיף להזרקה

Composition:

FIMBRAE TUPES 2 + 3 (FIM) 5 MCG/DOSE; PERTUSSIS TOXOID VACCINE 2.5 MCG/DOSE; FILAMENTOUS HAEMAGGLUTININ (FHA) 5 MCG/DOSE; PERTACTIN (PRN) 3 MCG/DOSE; DIPHTHERIA TOXOID 2 LF / 1 DOSES; TETANUS TOXOID 5 LF / 1 DOSES; INACTIVATED POLIO VIRUS (IPV) TYPE 1 40 DU/DOSE; INACTIVATED POLIO VIRUS (IPV) TYPE 2 8 DU/DOSE; INACTIVATED POLIO VIRUS (IPV) TYPE 3 32 DU/DOSE

Mode d'administration:

תוך-שרירי

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

SANOFI PASTEUR, FRANCE

Groupe thérapeutique:

DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS

Domaine thérapeutique:

DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS

indications thérapeutiques:

Active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . Adacel polio is not indicatd for primary immunisation. Adacel polio is not indicated for treating diseases caused by B. pertussis, C.Diphtheriae or c. tetani or by poliomyelitis infections.

Date de l'autorisation:

2015-01-31